Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening.
Exogene has raised $186K in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in October 2025.
Exogene's investors include Entrepreneurs First, R42 Group, Unruly Capital, Jude Gomila, Selvedge Venture.
Exogene is headquartered in London, United Kingdom.
Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening.
Exogene is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exogene — Funding & Investors." VCBacked, October 1, 2025, https://www.vcbacked.co/company/exogene. Accessed October 2, 2026.
VCBacked. (2025). Exogene — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/exogene
{{cite web |title=Exogene — Funding & Investors |url=https://www.vcbacked.co/company/exogene |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated